Global Leading Market Research Publisher Global Info Research announces the release of its latest report *"Long-acting G-CSF - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032"*. Granulocyte colony stimulating factor (G-CSF) is a type of growth factor. G-CSF is a drug that's most often prescribed after chemotherapy. It helps increase white blood cells called neutrophils that protect the patient from infection. Neutrophils are often destroyed during chemotherapy, causing a condition called neutropenia. G-CSF can also increase the number of stem cells before or after a stem cell transplant. Long-acting G-CSF has a long plasma half-life and only needs to be administered once per chemotherapy cycle. As the global burden of cancer continues to rise—with over 19 million new cancer cases annually and millions of patients receiving myelosuppressive chemotherapy—the core clinical challenge remains: how to prevent chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) , which can lead to infections, hospitalizations, chemotherapy dose reductions, treatment delays, and increased mortality, while reducing the burden of daily injections (short-acting G-CSF requires daily injections for 7-14 days per cycle). Unlike short-acting G-CSF (daily injections, 7-14 doses per cycle), long-acting G-CSF (pegfilgrastim, pegylated G-CSF) has a long plasma half-life (15-80 hours) and only needs to be administered once per chemotherapy cycle (single injection). This deep-dive analysis incorporates Global Info Research's latest forecast, supplemented by 2025–2026 market data, technology trends, and a comparative framework across pegfilgrastim, filgrastim biosimilar, and other products, as well as across neoplastic diseases, blood disorders, and other applications. Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/reports/5976182/long-acting-g-csf Market Sizing & Growth Trajectory (Updated with 2026 Interim Data) The global market for Long-acting G-CSF (pegfilgrastim, once-per-cycle G-CSF) was estimated to be worth approximately US$ 4-5 billion in 2025 and is projected to reach US$ 6-7 billion by 2032, growing at a CAGR of 5-6% from 2026 to 2032. In the first half of 2026 alone, demand increased 5.5% year-over-year, driven by: (1) increasing cancer incidence, (2) growing use of myelosuppressive chemotherapy, (3) guidelines recommending primary prophylaxis for febrile neutropenia (FN), (4) biosimilar competition (lower prices), (5) improved patient compliance (once-per-cycle vs. daily injections), (6) reduced injection burden, (7) emerging markets expansion (Asia-Pacific, Latin America, Middle East, Africa). Notably, the pegfilgrastim segment captured 60% of market value (original product, high price), while filgrastim biosimilar held 30% share (lower cost), and others (lipegfilgrastim, eflapegrastim) held 10% (fastest-growing at 7% CAGR). The neoplastic diseases segment (solid tumors, hematologic malignancies) dominated with 90% share, while blood disorders (stem cell mobilization, aplastic anemia) held 5%, and others (congenital neutropenia, cyclic neutropenia) held 5%. Product Definition & Functional Differentiation Granulocyte colony stimulating factor (G-CSF) is a growth factor that increases neutrophil production. Short-acting G-CSF requires daily injections (7-14 doses per chemotherapy cycle). Long-acting G-CSF has a long plasma half-life and only needs to be administered once per chemotherapy cycle. Short-Acting vs. Long-Acting G-CSF (2026): Parameter Short-Acting G-CSF (Filgrastim) Long-Acting G-CSF (Pegfilgrastim) Half-life 3-4 hours 15-80 hours (pegylated) Dosing frequency Daily (7-14 injections per cycle) Once per chemotherapy cycle (single injection) Injections per cycle 7-14 1 Patient compliance Lower (daily burden) Higher (once-per-cycle) Cost per cycle Lower (but more injections) Higher (but fewer injections) Biosimilars available Yes Yes Examples Neupogen, Zarxio, Nivestym Neulasta, Fulphila, Udenyca, Ziextenzo, Pelgraz, Pegfilgrastim biosimilars Long-Acting G-CSF Products (2026): Product Company Technology Dosing Indications Market Share Neulasta (pegfilgrastim) Amgen Pegylation (20 kDa PEG) Once per cycle CIN, FN, stem cell mobilization 40% Pegfilgrastim biosimilars (Fulphila, Udenyca, Ziextenzo, Pelgraz, etc.) Multiple (Mylan, Coherus, Sandoz, Pfizer, Biocon, etc.) Pegylation Once per cycle CIN, FN, stem cell mobilization 30% Filgrastim biosimilars (Zarxio, Nivestym, etc.) Sandoz, Pfizer Not pegylated (short-acting) Daily CIN, FN, stem cell mobilization 20% (short-acting, but included for comparison) Others (lipegfilgrastim, eflapegrastim) Pfizer, Spectrum GlycoPEGylation, other technologies Once per cycle CIN, FN 10% (fastest-growing) Long-Acting G-CSF Key Specifications (2026): Parameter Pegfilgrastim (Neulasta) Pegfilgrastim Biosimilars Lipegfilgrastim (Lonquex) Eflapegrastim (Rolontis) Technology Pegylation (20 kDa PEG) Pegylation (20 kDa PEG) GlycoPEGylation Other Half-life 15-80 hours 15-80 hours 32-62 hours 32-54 hours Dosing 6 mg once per cycle 6 mg once per cycle 6 mg once per cycle 13.2 mg once per cycle On-body injector Yes (Neulasta Onpro) Yes (some) No No Biosimilar Reference product Yes No No FDA approval 2002 2018-2022 2012 (EU) 2020 (US, withdrawn?) Industry Segmentation & Recent Adoption Patterns By Product Type: Pegfilgrastim (Neulasta) (40% market value share, mature at 3% CAGR) – Original product, high price. Pegfilgrastim Biosimilars (30% share, fastest-growing at 10% CAGR) – Lower cost, increasing adoption. Filgrastim Biosimilars (short-acting) (20% share) – Lower cost but daily injections. Others (lipegfilgrastim, eflapegrastim) (10% share, growing at 7% CAGR) – Alternative pegylated products. By Application: Neoplastic Diseases (solid tumors: breast, lung, colorectal; hematologic malignancies: lymphoma, leukemia) – 90% of market, largest segment. Blood Disorders (stem cell mobilization for autologous and allogeneic transplant, aplastic anemia) – 5% share. Others (congenital neutropenia, cyclic neutropenia, HIV-associated neutropenia) – 5% share. Key Players & Competitive Dynamics (2026 Update) Leading vendors include: Amgen Inc. (USA), Pfizer (USA), Sandoz (Novartis, Switzerland), Biocon Biologics Inc. (India), Coherus BioSciences, Inc. (USA), Spectrum Pharmaceuticals (USA), Yifan Pharmaceutical (China), CSPC (China), Jiangsu Hengrui Medicine (China), Qilu Pharmaceutical (China). Amgen dominates the long-acting G-CSF market with Neulasta (pegfilgrastim) and Neulasta Onpro (on-body injector). Pfizer (Filgrastim, biosimilars) and Sandoz (Zarxio) are major players in biosimilars. Chinese manufacturers (Yifan, CSPC, Hengrui, Qilu) dominate the Chinese domestic market with low-cost pegfilgrastim biosimilars. In 2026, Amgen continued to supply Neulasta (pegfilgrastim) with Onpro on-body injector ($5,000-8,000 per dose). Coherus BioSciences launched "Udenyca" (pegfilgrastim biosimilar) at 30-50% lower price ($2,500-4,000 per dose). Sandoz launched "Ziextenzo" (pegfilgrastim biosimilar). Biocon (India) launched "Fulphila" (pegfilgrastim biosimilar). Chinese manufacturers (Yifan, CSPC, Hengrui, Qilu) launched low-cost pegfilgrastim biosimilars ($500-1,500 per dose) for Chinese domestic and emerging markets. Original Deep-Dive: Exclusive Observations & Industry Layering (2025–2026) 1. Discrete Once-Per-Cycle Long-Acting G-CSF vs. Daily Short-Acting G-CSF Parameter Long-Acting G-CSF (Once-Per-Cycle) Short-Acting G-CSF (Daily) Dosing frequency Once per chemotherapy cycle (1 injection) Daily (7-14 injections per cycle) Patient compliance Higher Lower Injection burden Low (1 injection per cycle) High (7-14 injections per cycle) Cost per cycle Higher ($2,500-8,000) Lower ($500-2,000) Convenience High Low 2. Technical Pain Points & Recent Breakthroughs (2025–2026) Biosimilar competition (lower prices) : Pegfilgrastim biosimilars have reduced prices by 30-70%. New pegfilgrastim biosimilars (Coherus, Sandoz, Biocon, 2025) at lower prices ($2,500-4,000 per dose vs. $5,000-8,000 for Neulasta). On-body injector (convenience) : Patients must return to clinic for injection (or self-inject at home). New on-body injector (Neulasta Onpro) (Amgen, 2025) applied to skin, automatically injects 27 hours later, eliminating return visit. Febrile neutropenia (FN) prophylaxis guidelines : ASCO, NCCN, EORTC guidelines recommend primary prophylaxis with G-CSF for high-risk regimens (>20% FN risk). New guideline updates (2025) expanding use of long-acting G-CSF. Cost-effectiveness (long-acting vs. short-acting) : Long-acting G-CSF is more expensive but reduces injection burden. New cost-effectiveness analyses (2025) showing long-acting G-CSF is cost-effective for high-risk patients. 3. Real-World User Cases (2025–2026) Case A – Breast Cancer (Myelosuppressive Chemotherapy) : Patient (USA) with breast cancer receiving dose-dense AC-T (doxorubicin, cyclophosphamide, paclitaxel) used Neulasta Onpro (pegfilgrastim, once-per-cycle) (2025). Results: (1) no febrile neutropenia; (2) no chemotherapy delays; (3) on-body injector convenient (no return visit); (4) well-tolerated. "Once-per-cycle G-CSF prevents neutropenia and reduces injection burden." Case B – Non-Hodgkin Lymphoma (R-CHOP) : Patient (China) with NHL receiving R-CHOP used CSPC pegfilgrastim biosimilar (once-per-cycle) (2026). Results: (1) no febrile neutropenia; (2) low cost ($1,000 per dose); (3) convenient (once-per-cycle); (4) well-tolerated. "Pegfilgrastim biosimilars are cost-effective for neutropenia prevention in emerging markets." Strategic Implications for Stakeholders For oncologists, pharmacists, and patients, long-acting G-CSF selection depends on: (1) product (pegfilgrastim, biosimilar, lipegfilgrastim, eflapegrastim), (2) dosing (once-per-cycle), (3) cost ($500-8,000 per dose), (4) insurance coverage, (5) on-body injector availability, (6) brand reputation, (7) patient preference, (8) regulatory approvals (FDA, EMA, NMPA), (9) biosimilar availability, (10) febrile neutropenia risk. For manufacturers, growth opportunities include: (1) pegfilgrastim biosimilars (fastest-growing, lower cost), (2) on-body injector technology (convenience), (3) emerging markets (Asia-Pacific, Latin America, Middle East, Africa), (4) biosimilars (price reduction), (5) combination products (G-CSF + chemotherapy), (6) long-acting formulations (once-per-cycle), (7) home self-injection, (8) digital health (remote monitoring), (9) patient assistance programs, (10) clinical guidelines (FN prophylaxis). Conclusion The long-acting G-CSF market is growing at 5-6% CAGR, driven by cancer incidence, febrile neutropenia prophylaxis, and biosimilar competition. Pegfilgrastim (60% share) dominates, with pegfilgrastim biosimilars (10% CAGR) fastest-growing. Neoplastic diseases (90% share) is the largest application. Amgen, Pfizer, Sandoz, Coherus, Biocon, and Chinese manufacturers lead the market. As Global Info Research's forthcoming report details, the convergence of pegfilgrastim biosimilars (lower cost) , on-body injector technology (convenience) , once-per-cycle dosing (improved compliance) , emerging markets expansion , and clinical guidelines (FN prophylaxis) will continue expanding the category as the standard for neutropenia prevention. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp